小分子-药物结合物:针对性治疗的新兴药物设计策略
Xiaolong Wang1, Can Guo1, Jikuan Shao1
1School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Journal of medicinal chemistry
|November 22, 2025
概括
小分子药物联合体 (SMDCs) 提供了一个有前途的向治疗方法,克服了传统化疗和抗体药物联合体 (ADCs) 的局限性. 本综述探讨了SMDC的设计,目标和癌症治疗的未来潜力.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
背景情况:
- 传统化疗缺乏特异性,导致严重的副作用.
- 向治疗,包括抗体与药物联合体 (ADCs),代表了精准医学的进步.
- 小分子-药物联结物 (SMDCs) 作为一种新型的向疗法类别,与ADC相比具有更好的特性.
研究的目的:
- 提供关于小分子-药物联合体 (SMDC) 结构和治疗点的全面概述.
- 分析SMDC在固体瘤治疗中的优势和挑战.
- 总结新兴的设计策略,以提高SMDC的有效性和安全性.
主要方法:
- 小分子-药物联合体 (SMDCs) 的文献综述.
- 分析SMDC结构,准机制和治疗应用.
- 评估药物动力学特性,细胞透和免疫性.
- 讨论诸如半衰期,目标外毒性和耐药性等挑战.
- 创新的SMDC设计策略的总结.
主要成果:
- SMDCs表现出有利的药理动力学,增强的细胞透性和非免疫性.
- 在固体瘤中观察到显著的治疗潜力.
- 关键的挑战包括短半衰期,潜在的目标外毒性和获得的耐药性.
- 新兴的设计旨在优化SMDC性能并克服局限性.
结论:
- 小分子药物合物 (SMDCs) 在向癌症治疗方面取得了重大进展.
- 进一步开发SMDC有望为更有效,更安全的癌症治疗提供希望.
- 解决半衰期,毒性和耐药性的挑战对于临床成功至关重要.
更多相关视频
08:47Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
Published on: March 6, 2019
9.9K
10:38Synthesis of Functionalized 10-nm Polymer-coated Gold Particles for Endothelium Targeting and Drug Delivery
Published on: January 15, 2018
13.0K
相关概念视频
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Phase II Conjugation Reactions: Overview
737
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
737
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drug-Receptor Bonds
4.2K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
4.2K
